VTAK (Catheter Precision) — Customer Relationships and Commercial Footprint

Catheter Precision (VTAK) sells a mix of capital equipment, consumables and software services to hospital electrophysiology labs and distributors, monetizing through one-time hardware and disposable sales plus recurring software‑upgrade contracts and distributor channels. Revenue drivers are product sales of the VIVO mapping system and the newer LockeT suture retention device, supplemented by multi‑year software upgrade arrangements and independent distributors for EMEA expansion. For a concise business-risk view and more relationship mapping, visit https://nullexposure.com/.

Why customers matter: a compact investor thesis

Catheter Precision is a narrowly focused medical‑device operator with concentrated revenue lines and a two‑pronged go‑to‑market: direct sales to leading hospitals for its VIVO system and partner distribution to accelerate international adoption of LockeT. The company’s commercial thesis rests on converting hospital evaluations into large, episodic purchases of systems and recurring sales of disposables and software services; a small number of large hospital customers currently account for a meaningful share of revenue.

Detailed customer relationships (each recorded result)

FuMedica AG — strategic distributor announcement (Mar 2026)

Catheter Precision announced a distribution agreement with FuMedica AG to bring the LockeT product to Switzerland, establishing a local commercial channel for EMEA expansion. According to MarketScreener (reported March 10, 2026), FuMedica will act as a regional distributor for LockeT.

Centre Hospitalier Universitaire (CHU) de Rennes — purchase order (Jul 2025)

CHU Rennes placed a purchase order, marking one of the company’s first significant European hospital commercial transactions for VIVO. GlobeNewswire reported the CHU Rennes purchase order in July 2025 as one of Catheter Precision’s early European wins.

FuMedica AG — corporate release via ManilaTimes (Oct 2025)

A ManilaTimes republish of the company release reiterated the strategic distribution tie to FuMedica AG and emphasized FuMedica's status as a Swiss medical device distributor. The ManilaTimes item (October 16, 2025) relays the company’s channel expansion plans through FuMedica.

University Clinical Center Ljubljana — VIVO purchase order (May 2026)

Catheter Precision reported receipt of a VIVO purchase order from the University Clinical Center Ljubljana, signaling adoption in Central Europe. The Globe and Mail press release (May 2026) identifies the Ljubljana installation as a new customer order for VIVO.

Centre Hospitalier Régional Universitaire (CHRU) Nancy — third VIVO installation in France (Nov 2025)

CHRU Nancy installed Catheter Precision’s third VIVO system in France, reinforcing the company’s foothold in leading European hospitals. GlobeNewswire covered the November 18, 2025 announcement noting the CHRU Nancy installation as the third French deployment.

CHU Rennes — second VIVO deployment referenced in rollout narrative (Nov 2025)

The company referenced a second VIVO deployment at CHU Rennes in its European activity summary, describing it as “Catheter Precision’s largest purchase order in Europe” at the time. That detail was included in the GlobeNewswire release (November 18, 2025) covering European installations.

HC21 — U.K. distribution partner for LockeT (Mar 2026)

Catheter Precision partnered with HC21, a U.K. distributor, to bring LockeT to the U.K. market, creating a local route to market for hospital sales and evaluations. A StockTwits news article (reported March 2026) summarized the company's distribution partnership with HC21.

Northside hospitals in Atlanta — evaluation pipeline mention (Feb 2026)

Catheter Precision listed Northside hospitals in Atlanta among high‑profile U.S. sites where LockeT evaluations have been completed or are near completion, indicating active prospecting at tier‑one hospitals. The company’s accelerated momentum release was republished via ManilaTimes (February 4, 2026) and names Northside among targeted U.S. hospital evaluators.

Scripps (Southern California) — evaluation pipeline mention (Feb 2026)

Scripps in Southern California is cited as a hospital where LockeT evaluations are underway or completed, highlighting U.S. adoption efforts outside the East Coast academic centers. The ManilaTimes republish of the company release (February 4, 2026) lists Scripps among the hospitals cited.

University of Michigan — evaluation pipeline mention (Feb 2026)

University of Michigan appears on the company’s list of leading U.S. hospitals completing or pending evaluations, indicating engagement with major academic electrophysiology programs. The ManilaTimes republish (February 4, 2026) relays this evaluation status.

John’s Hopkins and Beth Israel (Boston) — marquee evaluation mentions (Feb 2026)

Catheter Precision named John’s Hopkins and Beth Israel in Boston among high‑repute hospitals in its evaluation and approval pipeline, underscoring the company’s focus on obtaining reference installations at leading U.S. academic centers. The company’s accelerated momentum announcement (ManilaTimes/GlobeNewswire, February 4, 2026) lists these institutions.

Commercial and operational constraints that shape the model

The public disclosures and releases imply a small‑company commercial posture with specific structural characteristics that investors should weigh:

• Contracting posture: mix of one‑time system sales and recurring software upgrade commitments. The company recognizes software upgrades as stand‑ready services that are billed (and recognized) over contract terms of one or multiple years, indicating recurring revenue potential through software.
• Customer concentration is material. Management notes that a handful of customers accounted for a majority of revenues in prior years, with two accounts representing 53% of VIVO system sales in 2023 and several customers aggregating ~62% of revenues in 2024; this concentration creates pronounced revenue volatility tied to few accounts.
• Geography is international and concentrated in EMEA and North America. Catheter derives a meaningful portion of sales outside the U.S. (34% in recent reporting) and uses independent distributors to scale in Europe and the UK, which supports cross‑border growth but adds channel risk.
• Counterparty mix spans hospitals, non‑profits and individual physician adoption. Filings reference charitable investors and significant use by individual physicians and leading hospital systems, indicating heterogeneous buyer types and referral dynamics.
• Segments span hardware, manufacturing and software. The firm sells a hardware mapping system and LockeT devices, manufactures medical technologies, and sells software services—resulting in multi‑disciplinary commercial and manufacturing requirements.
• Relationship lifecycle: active and early‑ramping. VIVO has recorded more than 1,000 procedures and LockeT recognized initial sales in 2024; deployments are still in an adoption phase, with evaluations ongoing at major institutions.

What investors should watch next

• Conversion of high‑profile evaluations to anchor purchases at the referenced U.S. academic hospitals will materially change revenue visibility.
• Distributor performance in EMEA (FuMedica, HC21) will determine the pace of non‑U.S. revenue growth and local market penetration.
• Customer concentration risk mitigation—new, diversified customers and repeat consumable revenue will reduce volatility.

For a consolidated view of Catheter Precision’s commercial network and to track new relationship disclosures, see https://nullexposure.com/.

Bottom line

Catheter Precision operates a focused, high‑leverage commercial model: a small number of large hospital wins drive outsized revenue swings, while distributor partnerships and software upgrades create pathways to recurring revenue. Near‑term valuation sensitivity hinges on successful conversion of hospital evaluations and predictable repeat consumable or software revenue. Investors should monitor distributor rollouts in Switzerland and the U.K., plus the outcome of evaluations at Johns Hopkins, University of Michigan, and other marquee accounts.